Broad market issuer Valeant Pharmaceuticals today placed $1.5 billion of eight-year notes via sole bookrunner Barclays. Prior to pricing, the offering was upsized by $500 million. Proceeds will be used to fund a tender offer for the borrower’s 7%, 6.375%, and 5.375% notes due 2020. Valeant last month placed a $750 million add-on to its secured notes dueClick here to read more »
The post Valeant Pharma Prices $1.5B High Yield Offering to Refi Maturing Debt appeared first on HighYieldBond.com.
